{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:25:25Z","timestamp":1744172725540,"version":"3.40.3"},"reference-count":30,"publisher":"Universidad Nacional de Colombia","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. salud p\u00fablica"],"abstract":"<jats:p>La contaminaci\u00f3n ambiental por medicamentos es un problema ambiental emergente y una preocupaci\u00f3n de salud p\u00fablica. Se han detectado f\u00e1rmacos en diversos ecosistemas, donde han causado impactos negativos, y dadas sus propiedades bioactivas se consideran potencialmente da\u00f1inos para diversas especies. La ecofarmacovigilancia estudia la detecci\u00f3n, la evaluaci\u00f3n, la comprensi\u00f3n y la prevenci\u00f3n de los efectos adversos relacionados con la presencia de f\u00e1rmacos en el ambiente. El presente ensayo analiza la ecofarmacovigilancia mediante un paralelo con el libro Primavera silenciosa, se resaltan vac\u00edos de conocimiento y se aborda la problem\u00e1tica con un enfoque que destaca aspectos sociales de los problemas de salud-enfermedad-cuidado. Se se\u00f1ala que el abordaje actual de la ecofarmacovigilancia pierde de vista el papel determinante de las relaciones sociales y se enfoca en la b\u00fasqueda de causas inmediatas, en el corto plazo y en el estudio de factores aislados. Se observa la necesidad de un replanteamiento te\u00f3rico del problema, donde se resalten las m\u00faltiples relaciones ecosociales. En la actualidad, como sociedad, se est\u00e1 ante la posibilidad de conocer, replantear y tomar acciones frente a la forma en que los seres humanos se relacionan entre s\u00ed y con la naturaleza y c\u00f3mo se asumen las cuestiones de salud-enfermedad-cuidado.<\/jats:p>","DOI":"10.15446\/rsap.v27n1.111296","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T19:59:12Z","timestamp":1744142352000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["La perspectiva salud-ambiente como herramienta para la ecofarmacovigilancia","The health-environment perspective as a tool for ecopharmacovigilance"],"prefix":"10.15446","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-8809","authenticated-orcid":false,"given":"Diego Mauricio","family":"Quijano Prieto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6812-5382","authenticated-orcid":false,"given":"Jos\u00e9 Gilberto","family":"Orozco D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6146","published-online":{"date-parts":[[2025,1,1]]},"reference":[{"key":"2560232","doi-asserted-by":"crossref","unstructured":"1. Velo G, Moretti U. Ecopharmacovigilance for better health. Drug Saf an Int J Med Toxicol drug Exp. 2010; 33(11):963\u20138. https:\/\/doi.org\/10.2165\/11539380-000000000-00000.","DOI":"10.2165\/11539380-000000000-00000"},{"key":"2560233","doi-asserted-by":"crossref","unstructured":"2. Moreno R\u00edos AL, Gutierrez-Suarez K, Carmona Z, Ramos CG, Silva Oliveira LF. Pharmaceuticals as emerging pollutants: Case naproxen an overview. Chemosphere. 2022; 291:132822. https:\/\/doi.org\/10.1016\/j.chemosphere.2021.132822.","DOI":"10.1016\/j.chemosphere.2021.132822"},{"key":"2560234","doi-asserted-by":"crossref","unstructured":"3. K\u00fcmmerer K. Pharmaceuticals in the Environment. Annu Rev Environ Resour. 2010; 35(1):57\u201375. https:\/\/doi.org\/10.1146\/annurev-environ-052809-161223.","DOI":"10.1146\/annurev-environ-052809-161223"},{"key":"2560235","doi-asserted-by":"crossref","unstructured":"4. Gonz\u00e1lez Pe\u00f1a OI, L\u00f3pez Zavala M\u00c1, Cabral Ruelas H. Pharmaceuticals market, consumption trends and disease incidence are not driving the pharmaceutical research on water and wastewater. Int J Environ Res Public Health. 2021; 18(5):1\u201337. https:\/\/doi.org\/10.3390\/ijerph18052532.","DOI":"10.3390\/ijerph18052532"},{"key":"2560236","doi-asserted-by":"crossref","unstructured":"5. W\u00f6hler L, Niebaum G, Krol M, Hoekstra AY. The grey water footprint of human and veterinary pharmaceuticals. Water Res X. 2020; 7. https:\/\/doi.org\/10.1016\/j.wroa.2020.100044.","DOI":"10.1016\/j.wroa.2020.100044"},{"key":"2560237","unstructured":"6. Carson R. Primavera silenciosa. Barcelona: Editorial Cr\u00edtica; 2005."},{"key":"2560238","doi-asserted-by":"crossref","unstructured":"7. Smith MB. \u201cSilence, Miss Carson!\u201d Science, gender, and the reception of \u201cSilent Spring.\u201d Fem Stud. 2001; 27(3):733\u201352. https:\/\/doi.org\/10.2307\/3178817.","DOI":"10.2307\/3178817"},{"key":"2560239","doi-asserted-by":"crossref","unstructured":"8. K\u00fcmmerer K. Why Green and Sustainable Pharmacy? En: K\u00fcmmerer K, Hempel M, editores. Green and sustainable pharmacy. Heidelberg: Springer Berlin Heidelberg; 2010. https:\/\/doi.org\/10.1007\/978-3-642-05199-9_1.","DOI":"10.1007\/978-3-642-05199-9"},{"key":"2560240","doi-asserted-by":"crossref","unstructured":"9. Oaks JL, Gilbert M, Virani MZ, Watson RT, Meteyer CU, Rideout BA, et al. Diclofenac residues as the cause of vulture population decline in Pakistan. Nature. 2004; 427(6975):630\u20133. https:\/\/doi.org\/10.1038\/nature02317.","DOI":"10.1038\/nature02317"},{"key":"2560241","doi-asserted-by":"crossref","unstructured":"10. Richards NL, Gilbert M, Taggart M, Naidoo V. A cautionary tale: Diclofenac and its profound impact on vultures. Encycl Anthr. 2018;1\u20135:247\u201355. http:\/\/dx.doi.org\/10.1016\/B978-0-12-809665-9.09990-0.","DOI":"10.1016\/B978-0-12-809665-9.09990-0"},{"key":"2560242","doi-asserted-by":"crossref","unstructured":"11. Watson RT, Gilbert M, Oaks JL, Virani M. The collapse of vulture populations in South Asia. Biodiversity. 2004; 5(3):3\u20137. https:\/\/doi.org\/10.1080\/14888386.2004.9712733.","DOI":"10.1080\/14888386.2004.9712733"},{"key":"2560243","doi-asserted-by":"crossref","unstructured":"12. Carlsson C, Johansson A-K, Alvan G, Bergman K, K\u00fchler T. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. Sci Total Environ. 2006; 364(1\u20133):67\u201387. https:\/\/doi.org\/10.1016\/j.scitotenv.2005.06.036.","DOI":"10.1016\/j.scitotenv.2005.06.035"},{"key":"2560244","doi-asserted-by":"crossref","unstructured":"13. Brodin T, Fick J, Jonsson M, Klaminder J. Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations. Science. 2013; 339(6121):814\u20135. https:\/\/doi.org\/10.1126\/science.1226850.","DOI":"10.1126\/science.1226850"},{"key":"2560245","unstructured":"14. Lockwood S, Sa\u00efdi N, Morgan VA. Options for a strategic approach to pharmaceuticals in the environment - Task 1 Report [Internet]. 2016. Disponible en: https:\/\/bit.ly\/3XebCD4."},{"key":"2560246","unstructured":"15. OMS. Resistencia a los antimicrobianos [Internet]. 2020. Consultado en Abril 2022. Disponible en: https:\/\/bit.ly\/3EP8cAd."},{"key":"2560247","unstructured":"16. Comisi\u00f3n Europea. Comunicaci\u00f3n de la Comisi\u00f3n al Parlamento Europeo, al Consejo y al Comit\u00e9 econ\u00f3mico y Social Europeo. Enfoque estrat\u00e9gico de la Uni\u00f3n Europea en materia de productos farmac\u00e9uticos en el medio ambiente [Internet]. Bruselas; 2019. Disponible en: https:\/\/bit.ly\/3EOn6qx."},{"key":"2560248","doi-asserted-by":"crossref","unstructured":"17. Taylor D, Senac T. Human pharmaceutical products in the environment - The \u201cproblem\u201d in perspective. Chemosphere. 2014; 115:95-9. https:\/\/doi.org\/10.1016\/j.chemosphere.2014.01.011.","DOI":"10.1016\/j.chemosphere.2014.01.011"},{"key":"2560249","unstructured":"18. Jones OAH, Voulvoulis N, Lester JN. Potential impact of pharmaceuticals on environmental health. Bull World Health Organ. 2003; 81(10):768\u20139."},{"key":"2560250","doi-asserted-by":"crossref","unstructured":"19. Caban M, Stepnowski P. How to decrease pharmaceuticals in the environment? A review. Environ Chem Lett [Internet]. 2021; 19(4):3115\u201338. Disponible en: https:\/\/bit.ly\/4i9wJ1d.","DOI":"10.1007\/s10311-021-01194-y"},{"key":"2560251","unstructured":"20. European Medicines Agency. Guideline on the environmental risk assessment of medicinal products for human use [Internet]. 2006. Disponible en: https:\/\/bit.ly\/41ryD88."},{"key":"2560252","unstructured":"21. The European Union. Chemicals in the environment and their health implications. The European Union takes action [Internet]. 2012. Disponible en: https:\/\/tinyurl.com\/yscna6v8."},{"key":"2560253","doi-asserted-by":"crossref","unstructured":"22. Wilkinson JL, Boxall ABA, Kolpin DW, Leung KMY, Lai RWS, Wong D, et al. Pharmaceutical pollution of the world\u2019 s rivers. Proc Natl Acad Sci. 2022; 119(8):1\u201310. https:\/\/doi.org\/10.1073\/pnas.2113947119.","DOI":"10.1073\/pnas.2113947119"},{"key":"2560254","doi-asserted-by":"crossref","unstructured":"23. Wennmalm \u00c5, Gunnarsson B. Public Health Care Management of water pollution with pharmaceuticals: environmental classification and analysis of pharmaceutical residues in sewage water. Ther Innov Regul Sci. 2005; 39(3):291\u20137. https:\/\/doi.org\/10.1177\/009286150503900307%0A%0A.","DOI":"10.1177\/009286150503900307"},{"key":"2560255","unstructured":"24. Patneedi CB, Durga Prasadu K. Impact of pharmaceutical wastes on human life and environment. Rasayan J Chem [Internet]. 2015; 8(1):67\u201370. Disponible en: https:\/\/bit.ly\/3Xb0DKB."},{"key":"2560256","unstructured":"25. World Health Organization. Promoting rational use of medicines: core components [Internet]. WHO, Policy Perspectives on Medicines; 2002. Disponible en: https:\/\/bit.ly\/4gU0li4."},{"key":"2560257","doi-asserted-by":"crossref","unstructured":"26. Bain KT. Public Health Implications of Household Pharmaceutical Waste in the United States. Heal Serv Insights. 2010; 3. https:\/\/doi.org\/10.4137\/HSI.S4673.","DOI":"10.4137\/HSI.S4673"},{"key":"2560258","doi-asserted-by":"crossref","unstructured":"27. Al\u00f3s JI. Resistencia bacteriana a los antibi\u00f3ticos: una crisis global. Enferm Infecc Microbiol Clin. 2015; 33(10):692\u20139. https:\/\/doi.org\/10.1016\/j.eimc.2014.10.004.","DOI":"10.1016\/j.eimc.2014.10.004"},{"key":"2560259","doi-asserted-by":"crossref","unstructured":"28. Vel\u00e1squez G. Rethinking R&D for pharmaceutical products after the novel coronavirus COVID-19 shock. En: Vaccines, medicines and COVID-19. Springer Briefs in Public Health [Internet]. Springer; 2022. p. 59\u201372. Disponible en: https:\/\/bit.ly\/41v2vR6.","DOI":"10.1007\/978-3-030-89125-1_4"},{"key":"2560260","unstructured":"29. Orozco D\u00edaz JG. De la farmacovigilancia al monitoreo cr\u00edtico de los medicamentos. El proceso de registro de medicamentos en Colombia [Tesis de grado]. Universidad Nacional de Colombia; 2012 [Internet]. Disponible en: https:\/\/bit.ly\/3Qv1YYY."},{"key":"2560261","doi-asserted-by":"crossref","unstructured":"30. Iriart C, Waitzkin H, Breilh J, Estrada A, Merhy EE. Medicina social latinoamericana: aportes y desaf\u00edos. Rev Panam Salud P\u00fablica [Internet]. 2002; 12(2):128\u201336. Disponible en: https:\/\/bit.ly\/3Qwh7sQ.","DOI":"10.1590\/S1020-49892002000800013"}],"container-title":["Revista de Salud P\u00fablica"],"original-title":[],"link":[{"URL":"https:\/\/revistas.unal.edu.co\/index.php\/revsaludpublica\/article\/download\/111296\/94177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistas.unal.edu.co\/index.php\/revsaludpublica\/article\/download\/111296\/94177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T19:59:28Z","timestamp":1744142368000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistas.unal.edu.co\/index.php\/revsaludpublica\/article\/view\/111296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.15446\/rsap.v27n1.111296","relation":{},"ISSN":["2539-3596","0124-0064"],"issn-type":[{"value":"2539-3596","type":"electronic"},{"value":"0124-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}